clariti trio time upsid
target gener in-lin
net dbt
core growth anoth quarter strong opmx
revenu vs our/street core growth
incl tailwind fx headwind beat led
companion anim segment broad strength new product in-lin
portfolio livestock result core sale wors expect due
favor mix volum opex control margin came well-ahead gm
opm adj ep ahead street larg oper
top-lin margin gain first look detail
focu call investor convers afterward increment updat
provid simparica trio also known tripl combo zoetiss much-anticip
upcom product launch flea tick intern parasit first time
management outlin target first-year revenu contribut increment
sale ie net cannib simparica stand-alone parasiticid
focal point investor throughout much debat
much expect trio first year post-launch
view appropri target ie prior estim net
sale like meet investor expect although heard wide rang
target notabl management also indic expect us approv late
launch shortli slightli later invest commun hope
still despit march/april launch time target would make
sizeabl boost next-year revenu growth multi-year runway beyond
updat estim stay neutral po
tweak estim reflect updat guidanc cc sale
growth adj ep although much rais captur
beat reiter po still base price-to-earnings out-year estim
move nomin note revenu estim alreadi street-
high reiter neutral rate believ estim expect
reflect much upsid valuat remain all-time-high
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
zoeti global leader discoveri
develop manufactur
commerci anim health medicin
vaccin product companion
anim market well-diversifi portfolio
product line span eight core
speci five therapeut categori directli
market countri industri
believ zoeti benefit rise
demand companion product anim
health product particularli emerg market
new product product line extens
expand ancillari servic offer greater
oper work capit effici
opportunist invest acquisit and/or
partnership supplement growth howev
see valuat full given expect
alreadi high see limit room
po base ep estim back dcf
assum wacc termin growth rate roughli in-lin
current multipl albeit slightli higher recent valuat trend
believ justifi given upsid new product launch increment capit
deploy margin expans opportun defens natur
upsid risk continu ramp new product larger-than-expect contribut
futur launch acceler growth abaxi acquisit
downsid risk price object competit select market new product
launch competitor weaker demand anim health product regulatori issu
failur get approv key product pipelin macroeconom
condit currenc risk headwind relat regul antibiot use
michael ryskin herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
us life scienc diagnost tool anim health coverag cluster
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
